Th e diagnosis and management of acute syndromes involving the kidneys has become a multidisciplinary fi eld concerning not only nephrology and urology but also critical care medicine, cardiology, radiology, and other fi elds. With this evolution, the term acute renal failure, used for many years in clinical practice, has been replaced with the term AKI. Th e new term implies potentially reversible kidney injury or damage occurring in a time frame of hours or days and characterizing the disorder as 'acute' . Although the term 'injury' would not necessarily encompass kidney dysfunction without damage, the diagnosis of AKI syndrome is still made on the basis of a change in serum creatinine or urine output, both likely deriving from an altered glomerular fi ltration and therefore identifying more a dysfunction than damage. Histopathological changes during AKI have been studied [1] , but mostly in animal experiments. In fact, histopathological criteria are diffi cult to apply to the diagnosis of AKI in critically ill patients in whom kidney biopsy is usually considered to carry an inappropriate risk-to-benefi t ratio. Only recently, some attention has been given to signs of structural damage to the nephrons and its clinical relevance [2] .
Th ere are many reasons why a distinction should be made between kidney injury and dysfunction. Indeed, human kidneys have an important functional reserve; thus, dysfunction, especially when defi ned as an altered glomerular fi ltration, becomes evident only when more than 50% of the renal mass is compromised. Th e rise in serum creatinine is a sign of a glomerular fi ltration alteration that has been ongoing for hours or days. In the case of a transient decrease in glomerular fi ltration rate (GFR), creatinine may never rise signifi cantly. On the other hand, a rise in serum creatinine may occur in the presence of a constant creatinine generation when glomerular fi ltration has been impaired for at least 24 to 48 hours. Th e new steady state and the new level of serum creatinine will be set by the new level of glomerular fi ltration; at the new steady state, excretion will equal generation, but the required excretion will occur at the expense of a signifi cantly higher creatinine level. Standard AKI classifi cations such as the RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) criteria [3] or modifi ed RIFLE criteria [4] include as a diagnostic criterion even slight changes in serum
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creatinine (as low as 0.3 mg/dL), and validation studies of these criteria show that such conditions are associated with worse outcomes [5] . Once again, these approaches, though refi ned in comparison with previous criteria of diagnosis (often described by doubling serum creatinine or the need for dialysis), are still based on functional criteria and imply an altered GFR. Such alteration may have occurred long after the injury has taken place and long before the creatinine has reached the new higher steady level. Th is explains why a rise in serum creatinine is often a sign of severe kidney damage even if the rise in creatinine is minimal. In such a condition, information on the magnitude of tubular damage and other kidney tissues and functions is often not available.
Very recently, signifi cant contributions to the literature have shown that an early diagnosis of AKI can be made by using a single structural or functional biomarker (or a combination thereof ) capable of detecting kidney injury almost in real time [6] . Many studies with several thousands of patients have shown evidence that there is an additional value of new biomarkers not only because they allow a diagnosis to be made earlier [7] but also because they allow a kidney injury to be diagnosed even in the absence of a subsequent manifest dysfunction [2, 8] . What are the ideal characteristics for such biomarkers? Th ey must be specifi c for kidney injury, sensitive enough to detect even less severe insults, easy and rapid to measure, and inexpensive enough to make their use sustainable. A series of molecules have been evaluated over the years, and signifi cant advances have been made in the fi eld. Molecules such as NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury molecule-1), and Cys-C (cystatin-C) have demonstrated a peculiar capacity to detect an injury to the kidney well before the rise in serum creatinine can be observed. Th us, a new diagnostic approach to acute kidney syndromes can be envisaged. Such a biomarker-driven approach raises the question of whether AKI could be diagnosed even in the absence of the classic signs that have characterized the syndrome in the past. In other words, if we compare AKI with the acute coronary syndrome, in which an increase in troponin may be a suffi cient trigger for a diagnosis and a therapeutic intervention, the diagnosis of AKI could be made even in the absence of oliguria or increased creatinine levels. Th e fact that AKI is not clinically manifest does not necessarily mean that the kidney is intact and that the function is perfect. A subclinical entity may be unveiled by the new biomarkers and we should still call this entity AKI. In these circumstances, revised RIFLE or Acute Kidney Injury Network (AKIN) criteria should integrate one or more injury markers with creatinine, urine output, and/or other functional markers. Th is concept was recently proposed, expanding the spectrum of clinical conditions under the umbrella of AKI [9] . Today, we do not have suffi cient data to characterize the severity of the syndrome on the basis of structural biomarker levels alone and therefore the grading of the syndrome still relies on renal function markers. Nevertheless, this should not mean that we can neglect a clinical condition characterized by positive bio marker and negative creatinine fi ndings. In practice, we have a new class or stage of AKI that is diagnosed by tubular damage biomarkers such as NGAL and that may or may not evolve into a clinically manifest syndrome characterized by decreased GFR and increased serum creatinine. At this point, one would be tempted to call this AKIN stage 0 but this would imply no AKI. Th e same is true for a possible RIFLE 0 condition. In this substantial and not merely semantic discussion, we may speculate that AKIN stages better describe the severity of the syndrome, not because they signifi cantly diff er from RIFLE stages but because the terms 'risk' and 'injury' , typical of RIFLE, may lead to confusion. In fact, if a biomarker-positive, creatinine-negative patient is observed, he or she has probably received an 'injury' to his kidney but may still be in a preclinical (according to creatinine) phase. For this reason, we propose an additional criterion to the classic RIFLE or AKIN criteria since both are basically functiondriven: the new criterion is injury-driven and identifi es a sub clinical AKI that, however, is defi nitely an AKI. Th e new criterion also enables a timely diagnosis of 'prerenal' AKI and a more precise distinction of the term since during such a condition tubular damage biomarkers are negative but simultaneously a loss of fi ltration function is evident [6, 10] . For example, hypovolemia due to reduced fl uid intake or increased fl uid loss may cause a reduction in GFR, but the integrity and polarity of tubular cells may be preserved in the absence of infl ammation or ischemia. None theless, a prolonged and severe hypovolemia in patients with comorbidities may contribute to tubular damage, especially when hypoperfusion develops.
Isolated function loss or isolated damage, when occurring alone, is each suffi cient to constitute AKI, and the two occurring together -regardless of which one occurs fi rst -may progress to a combined function loss and damage. Table 1 presents the entities of AKI syndrome on the basis of renal fi ltration function and tubular damage markers.
Th is new approach has several implications. First, the diagnosis of AKI may include a larger spectrum of conditions, and the epidemiology of the syndrome may well change in terms of incidence and prevalence. In fact, a larger number of individuals may fall within the defi nition of AKI if function and injury criteria are used for diagnosis. Second, the concept of prevention or early organ protection or both may change, and we might be able to rewrite several sections of the chapter on pre ventive measures for AKI. Several interventions, in fact, have failed to provide positive results, even when pre vious laboratory and animal data were extremely encouraging. Th is may have to do with the timing in which the prevention/protection measure is applied. Th e condition in which a tubular damage biomarker is positive, even in the absence of a rise in serum creatinine (subclinical AKI), may become suffi cient to trigger interventions and protective strategies for the kidney. (Th is was not possible before, because we used only biomarkers of dysfunction, like creatinine, which are a mirror of a late phenomenon. Th us, interventions done in the past were always done too late.) Th ird, we may need to re-establish a term for renal function loss (for example, acute renal dysfunction), distinguishing it from AKI with tubular damage, or at least to provide a new staging classifi cation (subclinical AKI for patients who are biomarker-positive and creatinine-negative). Fourth, the accuracy and timeliness of diff erential diagnosis of the underlying cause of AKI (prerenal versus nonprerenal) may be improved.
More considerations on the concept of 'biomarker posi tivity' are needed. Biomarkers are becoming more and more reliable in terms of sensitivity and specifi city, and even high-sensitivity assays with extended range are becoming available. Th ese new assays have improved the capability of damage detection even below the classic cutoff values [11] . In such circumstances, sequential measure ments may be indicated to build biomarker curves capable of identifying trends characteristic of a transient or ongoing renal insult. Th is may open up a new frontier in the diagnosis of AKI and its consequences in terms of prevention and therapeutic strategies.
In conclusion, we are living in a post-creatinine world where creatinine should not be abandoned but we should move beyond it. What today is considered subclinical AKI (tubular damage biomarker positivity without dysfunc tion) can, thanks to the new biomarkers, be defi ned as AKI and we cannot aff ord to neglect such conditions when they are associated with negative outcomes. Th e accuracy of new biomarkers is crucial in this process, and we should start considering not only cutoff values but also trends and biomarker curves, especially now that high-sensitivity assays are becoming available. In other words, we must consider that subclinical AKI is still AKI.
